Cheaper semaglutide could change who gets treated, but affordability is not the same as readiness. When a blockbuster drug loses patent protection, the biggest shift is often not clinical but logistical: more manufacturers, more competition and wider access. That may help people who have struggled to obtain treatment, yet the public-health benefit will depend on whether health systems can screen, prescribe and monitor use safely and consistently.
The evidence base for semaglutide is strong for weight loss, but the real-world picture is more complicated. Trial results do not automatically translate into the same outcomes once a drug becomes widely available. Adherence, follow-up, dose escalation, side effects and discontinuation all shape results, and these practical factors can matter as much as the medicine itself. Lower prices may improve persistence, but only if patients can still access clinical support and trusted prescribing.
Generic entry also raises quality and misuse questions. A larger supply can reduce costs, but it can also attract counterfeit products, inappropriate sourcing and use outside approved channels. For a treatment class that may be taken long term, safety depends on more than the active ingredient: storage, manufacturing standards, labeling and monitoring all matter. That makes regulatory oversight and patient education part of the health story, not just market competition.
Finally, cheaper GLP-1 drugs should not crowd out prevention. Obesity is shaped by food environments, activity, sleep, stress and socioeconomic conditions. Medication can be an important tool, but it does not replace broader efforts to reduce risk and support sustained behaviour change. The most realistic outlook is a mixed one: generics may expand access, while long-term population health still depends on prevention, continuity of care and careful use.
Cheaper alternativesWeight-loss drugs feel so ubiquitous these days that itโs easy to forget how difficult it still is for much of the worldโs obese population to get them. Given high costs and supply constraints, fewer than 10% of everyone who could benefit from GLP-1 drugs get them, the World Health Organization recently warned. In some countries, patients could soon have cheaper options in the form of off-patent generic medications. The core patent for semaglutide, the key ingredient in Novo Nordiskโs popular Ozempic and Wegovy drugs, is set to expire in several markets over the next few months. As my colleagues and I report in this Bloomberg Big Take, dozens of companies have their sleeves rolled up to market copies of the drugs, likely paving the way for a price war. In India, Nomura analysts estimate prices could drop to as low as $15. The arrival of generics will be game-changing in terms of the cost, accessibility and availability of obesity therapies, according to Angie Jackson-Morris, director of program development and strategy at the World Obesity Federation. With patent protection falling in populous countries like China, India and Brazil, by one estimate, the change will affect a third of the worldโs adults living with obesity. In other markets such as the US and Europe, the semaglutide patents will stay in place until the 2030s. To be sure, semaglutide copycats arenโt going to be unleashed all at once. Canada, which became the first country to open the door to generics in early January, is still reviewing its first batch of applications. Some generic makers are initially targeting approval for treating diabetes, not weight loss. But price pressures are already being felt. In recent months, Novo Nordisk has cut the price of Wegovy in India and China, where the launch prices were already lower than developed markets, and its chief rival Eli Lilly has also slashed its price in China. Meanwhile, other drugmakers are developing medicines promising to be more effective, safer or easier to use than semaglutide. Things arenโt all rosy from here. The influx of new generics could exacerbate issues with drug misuse and counterfeit products. Jackson-Morris also urges governments not to view the treatments as a cure-all โ prevention and management are just as important. Obesity is โone of the biggest public health challenges. So it needs all brains, all organizations, and I think individuals, the media, everybody will have a role,โ she said. She cited the HIV epidemic, in which the virus-borne disease moved from a stigmatized, life-threatening condition to a manageable chronic one over two decades. โDrugs were an important part, but only one part of that.โ โ Amber Tong |
Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.